Treating patients with less advanced-stage disease and using more innovative agents is currently tested in the randomized phase 2 trial SAFIR02 (NCT02299999) in which genomics-matched, targeted treatments are used as maintenance after response or stabilization obtained by standard first- or second-line cytotoxic chemotherapy in HER2-negative advanced breast cancer patients. Here, ERBB2 is linked to breast cancer.